SI-BONE's Innovation Drives EBITDA Profitability and Revenue Growth

SI-BONE, Inc. (NASDAQ: SIBN) reported stronger-than-expected third-quarter 2025 financial results on November 10, 2025, with adjusted EBITDA turning positive and a revised revenue forecast that now anticipates $198 million to $200 million in annual sales. The medical device company, a global leader in sacropelvic disorder treatments, also announced a conference call to discuss its performance in detailSI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance.

The company's gross margin expanded to 79.8% in Q3 2025, up 75 basis points from 79.1% in the same period in 2024, driven by operational efficiencies. Operating expenses rose 11.9% to $44.2 million, reflecting higher commercial activity tied to new product launches and increased administrative costs. Despite this, operating losses narrowed by 29.5% to $5.4 million, while net losses improved by 30.6% to $4.6 million, or $0.11 per diluted share, compared to $6.6 million, or $0.16 per share, in the prior-year quarter.

Adjusted EBITDA surged to $2.3 million, reversing a $0.2 million loss in Q3 2024SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance.

SI-BONE's cash reserves remained stable at $145.7 million as of September 30, 2025, consistent with the previous quarter. The company raised its full-year 2025 guidance, projecting revenue growth of 18-20% to $198 million-$200 million and maintaining a gross margin of approximately 79.5%. These updates reflect confidence in the company's market position, with CEO David B. Robinson attributing the performance to "continued adoption of our minimally invasive solutions" and a growing global footprintSI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance.

The revised guidance underscores SI-BONE's resilience in a competitive healthcare landscape. Since pioneering minimally invasive sacroiliac joint surgery in 2009, the company has supported over 4,900 physicians in performing more than 135,000 procedures. Analysts note that the firm's focus on innovation and expanding indications for its technologies positions it to capture further market share in the orthopedic sectorSI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance.

A webcast and conference call to discuss the results are scheduled for November 10, 2025, at 4:30 p.m. Eastern Time. The event will be archived for at least 90 days, and live audio will be available on SI-BONE's investor relations pageSI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance.